AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04430985
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 1 in cycle 1-4: 100 mg/m2 intrahepatic administration Day 1 in cycle 5-8: oxaliplatin 85 mg/m2 i.v.
Trial: NCT04430985
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day 1 each cycle: 400 mg/m2 i.v. bolus, 2400 mg/m2 i.v.over 46 hrs
Trial: NCT04430985
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Day 3 in cycle 3 to 8: 3 mg/kg i.v.
Trial: NCT03142165
Drug: BMS-986263
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3 weekly doses of 90 mg infused intravenous administration
Trial: NCT03142165
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg intravenous administration
Trial: NCT03142165
Drug: Famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg intravenous administration
Trial: NCT00042978
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00042978
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00682500
Drug: Calfactant
RxNorm normalized name: Calfactant
DrugBank: Calfactant (DB06415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratracheal Instillation of 0.5 mL/cm of height of 60 mg/mL suspension in two aliquots at study entry. Repeat dosing 12 hours later if criteria are met.
Trial: NCT00682500
Drug: Room Air (placebo)
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 0.5 ml/cm height of air at study entry into the trachea. Repeat dosing at 12 hours if criteria are met
Trial: NCT02013154
Drug: DKN-01 150 mg
RxNorm normalized name: Dkk1-neutralizing monoclonal antibody dkn-01
DrugBank: Sirexatamab (DB17515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by IV infusion
Trial: NCT02013154
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by IV infusion
Trial: NCT02013154
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by IV infusion
Trial: NCT02013154
Drug: DKN-01 300 mg
RxNorm normalized name: Dkk1-neutralizing monoclonal antibody dkn-01
DrugBank: Sirexatamab (DB17515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by IV infusion
Trial: NCT03318159
Drug: Posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosing of posaconazole Posaconazole tablet 300 mg twice daily on day 1; Maintenance dose: 300 mg once daily on day 2 and thereafter. Treatment period: 4 weeks~\*if posaconazole tablet intolerance: posaconazole suspension 200mg tid
Trial: NCT01285544
Drug: Atorvastatin (Lipinon)
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: treatment of dyslipidemia administration : PO, qod
Trial: NCT01285544
Drug: Atorvastatin (Lipitor)
RxNorm normalized name: atorvastatin Oral Tablet [Lipitor]
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: treatment of dyslipidemia administration : PO, qod
Trial: NCT00034632
Drug: Posaconazole oral suspension
RxNorm normalized name: Posaconazole Oral Suspension
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01827605
Drug: BEAM
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEAM REGIMEN day -6 Carmustine\* 300 mg/ m2 i.v. in 250ml dextrose 5% solution~from day -5 to day -2 Cytarabine 200 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr Etoposide 100 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr day -1 Melphalan 140 mg/m2 i.v. in 100ml saline solution in 200 ml/hr~day 0~UReinfusion of autologous stem cells following this rules:~1. Patient collecting ≥6x106 CD34+ cells/kg use \>4x106 CD34+ cells/kg for ASCT and keep \>2x106 CD34+ cells/kg for back up;~2. Patient collecting 4-6x106 CD34+ cells/kg use \>2x106 CD34+ cells/kg for ASCT and keep \>2x106 CD34+ cells/kg for back up;~3. Patient collecting 2-4x106 CD34+ cells/kg use all CD34+ cells for ASCT and keep no back up.~day 2 Filgrastim or Lenograstim 5μg/Kg s.c. until ANC \> 1500/mmc
Trial: NCT03961503
Drug: Daptomycin (DAP) treatment
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group DAP : Daptomycin was administered at a dose of 8 mg/kg in thirty-minutes intravenous infusion every 24 hours in patients without severe impairment of kidney function or every 48 hours in case of GFR below 30 ml/min/m2. The creatine-kinase (CK) level was measured before the initiation of DAP and at least once a week to assess the occurrence of muscular toxicity defined by an increase of CK up to 3-fold the upper superior limit without any evidence of member ischaemia.
Trial: NCT00573417
Drug: modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: modafinil 100mg tablets. dose excalation up to 300mg
Trial: NCT03961503
Drug: Vancomycin (VAN) treatment
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group VAN : Vancomycin intravenous treatment was initiated by a loading dose of 30 mg/kg in 1 hour and followed by a continuous maintenance infusion dosing between 15 and 30 mg/kg/d. The VAN dose was adapted to achieve a target serum vancomycin steady-state concentration of 20-30 mg/L assessed by a daily pharmacologic monitoring (therapeutic drug monitoring).
Trial: NCT02568800
Drug: Prolonged Cefepime Infusion
DrugBank: Cefepime (DB01413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefepime infusion should last at least 4 hours with the aide of an infusion bomb
Trial: NCT02568800
Drug: Usual Cefepime Infusion
DrugBank: Cefepime (DB01413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefepime infusion occurs directly without the aide of an infusion bomb, lasting roughly thirty minutes
Trial: NCT00025272
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00025272
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00025272
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03679598
Drug: Alvelestat (MPH966)
RxNorm normalized name: Alvelestat
DrugBank: Alvelestat (DB11863)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alvelestat was developed as treatment for lung diseases like Chronic Obstructive Pulmonary Disease. Alevelestat works by blocking certain proteins in the body that are responsible for inflammation and damage to the lungs that can lead to COPD symptoms.
Trial: NCT03723824
Drug: grazoprevir 100 mg/ elbasvir 50 mg, Zepatier®
DrugBank: Elbasvir (DB11574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: grazoprevir 100 mg/ elbasvir 50 mg (Zepatier®, MSD) once daily for 12 weeks
Trial: NCT04788121
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The treatment group will receive Injection TXA 1gm intravenous (IV) over 15 minutes infusion dissolved in 100 ml normal saline (NS- 0.9% NaCl), followed by injection TXA 2 g IV over 12 hours infusion dissolved in a 500 ml NS
Trial: NCT00345176
Drug: Lutein/zeaxanthin and DHA/EPA
DrugBank: Lutein (DB00137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg lutein and 2 mg zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
Trial: NCT03375047
Drug: MRT5005
RxNorm normalized name: MRT5005
DrugBank: MRT5005 (DB18260)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulization of MRT5005
Trial: NCT02195583
Drug: Sodium fluoride (1426 ppm)
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
Trial: NCT02195583
Drug: Sodium fluoride (1150 ppm)
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base
Trial: NCT02195583
Drug: Sodium fluoride (250 ppm)
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base
Trial: NCT00004420
Drug: gamma-Linolenic acid
RxNorm normalized name: gamma-linolenic acid
DrugBank: Gamolenic acid (DB13854)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00685503
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02788240
Drug: Terlipressin 1- 4mg,if indicated
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02788240
Drug: Meropenem or Imepenem, if indicated
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03045562
Drug: Salvianolate injection
RxNorm normalized name: Salvianolic acid A
DrugBank: Salvianolic acid A (DB15246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be assigned to receive Salvianolate injection dissolved in 100ml of normal saline in catherter room setting,and following similar medicine once daily for 7 days.
Trial: NCT00623428
Drug: peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00623428
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00927069
Drug: Adalimumab every other week
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab 40mg injection every other week for 24 weeks
Trial: NCT00927069
Drug: Adalimumab Every Week
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab 40mg injection every week for the last 12 weeks of study.
Trial: NCT00397787
Drug: sunitinib malate
RxNorm normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT02450682
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anticoagulant agent for Atrial Fibrillation and undergo CIED generator change
Trial: NCT02450682
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anticoagulant agent for Atrial Fibrillation and undergo CIED generator change
Trial: NCT01244620
Drug: sitaxentan
RxNorm normalized name: Sitaxentan
DrugBank: Sitaxentan (DB06268)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: sitaxsentan 100 mg QD for 6 days
Trial: NCT01244620
Drug: tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tadalafil 40 mg QD for 6 days
Trial: NCT01244620
Drug: sitaxsentan
RxNorm normalized name: Sitaxsentan
DrugBank: Sitaxentan (DB06268)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: sitaxsentan 100 mg QD for 6 days
Trial: NCT02195583
Drug: Fluoride (0 ppm)
RxNorm normalized name: Hydrogen fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-zinc, 0ppm fluoride in a silica gel base
Trial: NCT02620696
Drug: netazepide
RxNorm normalized name: Netazepide
DrugBank: Netazepide (DB12355)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02573363
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given per standard of care
Trial: NCT02573363
Drug: Mitoxantrone Hydrochloride
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given per standard of care
Trial: NCT02573363
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT01244620
Drug: sitaxsentan
RxNorm normalized name: Sitaxsentan
DrugBank: Sitaxentan (DB06268)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: sitaxentan 100 mg QD for 6 days
Trial: NCT01244620
Drug: sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sildenafil 20 mg TID for 6 days
Trial: NCT03872128
Drug: Pregnenolone300
DrugBank: Pregnenolone (DB02789)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg
Trial: NCT01367535
Drug: SC Methylnaltrexone (MNTX)
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01367535
Drug: IV Methylnaltrexone (MNTX)
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01367535
Drug: Oral Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04341441
Drug: Hydroxychloroquine - Daily Dosing
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The daily hydroxychloroquine treatment arm will receive a 200 mg oral dose daily following day 1 dose of 400 mg orally once. This dose represents approximately half the standard weight-based dosing recommended for management of autoimmune diseases and therefore less likely to produce side effects than standard of care.~All treatment groups will receive placebo pills to have the patients take 2 pills a day.
Trial: NCT04341441
Drug: Hydroxychloroquine - Weekly Dosing
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The once weekly randomized treatment arm will receive the proposed dose of hydroxychloroquine for prophylaxis of malaria is 6.5 mg/kg per dose (maximum of 400 mg per dose) administered orally weekly on the same day of each week. This is based on the recommended dose for prophylaxis of malaria~All treatment groups will receive placebo pills to have the patients take 2 pills a day.
Trial: NCT05219942
Drug: Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: regular low dose insulin infusion 0.1 IU/Kg/hour and subcutaneous Glargine insulin (made by Sanofi®) within the first 2 hours of ICU admission. The dose of insulin glargine will be adjusted according to the calculated (eGFR \> 90 dose = 0.27 IU/kg/day, eGFR 60-89 dose = 0.25 IU/kg/day, eGFR \<60 dose = 0.19 IU/kg/day.
Trial: NCT00840073
Drug: Trandolapril 4 mg Tablets
RxNorm normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 4 mg, single-dose fed
Trial: NCT02648438
Drug: AZD7594 Solution for infusion (150 μg intravenous formulation)
RxNorm normalized name: meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solution for infusion 0.01 mg/ml; AZD7594 150 μg IV
Trial: NCT02210195
Drug: aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 125 mg daily for 8 weeks.
Trial: NCT00917150
Drug: tetomilast (OPC-6535)
RxNorm normalized name: Tetomilast
DrugBank: Tetomilast (DB05298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of 12.5mg OPC-6535, once daily for 24months
Trial: NCT00917150
Drug: tetomilast (OPC-6535)
RxNorm normalized name: Tetomilast
DrugBank: Tetomilast (DB05298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of 25mg OPC-6535, once daily for 24months
Trial: NCT00917150
Drug: tetomilast (OPC-6535)
RxNorm normalized name: Tetomilast
DrugBank: Tetomilast (DB05298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of 50 mg OPC-6535, once daily for 24months
Trial: NCT02074020
Drug: Blisibimod
RxNorm normalized name: Blisibimod
DrugBank: Blisibimod (DB12330)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via subcutaneous injection once per week
Trial: NCT02412852
Drug: Sodium nitrite
RxNorm normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained release formulation of sodium nitrite
Trial: NCT02491905
Drug: HL tablet
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00035022
Drug: BCX-1777
RxNorm normalized name: BCX-4161
DrugBank: Avoralstat (DB12120)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03234244
Drug: Bazedoxifene 20 mg
RxNorm normalized name: bazedoxifene 20 MG
DrugBank: Bazedoxifene (DB06401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To estimate the drug-drug interaction between Bazedoxifene and combination of Bazedoxifene and Cholecalciferol, Subject will take Bazedoxifene 20mg 1 tablet one time.
Trial: NCT03234244
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To estimate the drug-drug interaction between Cholecalciferol and combination of Bazedoxifene and Cholecalciferol, Subject will take Cholecalciferol 2 tablets one time.
Trial: NCT01689311
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
Trial: NCT01689311
Drug: Ergonovine
RxNorm normalized name: Ergonovine
DrugBank: Ergometrine (DB01253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergonovine, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
Trial: NCT03234244
Drug: Bazedoxifene 20mg and Cholecalciferol
RxNorm normalized name: bazedoxifene 20 MG
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For estimate the Drug-Drug Interaction, Subject will take Bazedoxifene 1 tablet and Cholecalciferol 2 tablets at once.
Trial: NCT02302976
Drug: cocaine hydrochloride
RxNorm normalized name: Cocaine Hydrochloride
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02302976
Drug: exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00042887
Drug: mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01689311
Drug: Prostaglandin F2alpha
RxNorm normalized name: Prostaglandin F2alpha tham
DrugBank: Dinoprost tromethamine (DB01160)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin F2alpha, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
Trial: NCT01689311
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
Trial: NCT02601625
Drug: Anifrolumab SC injection (300mg)
RxNorm normalized name: anifrolumab
DrugBank: Anifrolumab (DB11976)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300 mg of anifrolumab delivered as 2 separate 1 mL SC injections administered serially on Day 1
Trial: NCT02601625
Drug: Anifrolumab IV infusion (300mg)
RxNorm normalized name: anifrolumab
DrugBank: Anifrolumab (DB11976)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300 mg of anifrolumab delivered as an IV infusion over 30 minutes on Day 1
Trial: NCT02601625
Drug: Anifrolumab SC infusion (600mg)
RxNorm normalized name: anifrolumab
DrugBank: Anifrolumab (DB11976)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 600 mg of anifrolumab delivered as 4 mL SC by infusion pump on Day 1
Trial: NCT02601625
Drug: Anifrolumab placebo SC injection (300mg)
RxNorm normalized name: anifrolumab
DrugBank: Anifrolumab (DB11976)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300mg of placebo delivered as 2 separate 1 mL SC injections administered serially on Day 1
Trial: NCT02601625
Drug: Anifrolumab placebo IV infusion (300mg)
RxNorm normalized name: anifrolumab
DrugBank: Anifrolumab (DB11976)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 600mg of placebo delivered as an IV infusion over 30 minutes on Day 1
Trial: NCT02601625
Drug: Anifrolumab placebo SC infusion (600mg)
RxNorm normalized name: anifrolumab
DrugBank: Anifrolumab (DB11976)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 600 mg of placebo delivered as 4 mL SC by infusion pump on Day 1
Trial: NCT05640531
Drug: WCK 771 IV Infusion
RxNorm normalized name: Wck 771 free base
DrugBank: Levonadifloxacin (DB16219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects will receive intravenous infusion of WCK 771
Trial: NCT03708458
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the investigators aimed to perform a comparative study, evaluating the efficacy of three prophylactic approaches aiming to reduce the risk of PEP, using indomethacin and/or N-acetylcysteine -NAC, in different regimens
Trial: NCT01422109
Drug: clopidogrel & aspirin
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: clopidogrel tablet(75mg) + aspirin capsules(100mg) by oral
Trial: NCT00406380
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes